tldrdailynews.com logo
Tag

Wegovy

All articles tagged with #wegovy

Novo Nordisk rolls out Wegovy subscription to lock in predictable GLP-1 prices
business11 days ago

Novo Nordisk rolls out Wegovy subscription to lock in predictable GLP-1 prices

Novo Nordisk launched a multi-month Wegovy subscription for its injectable doses and the high-dose pill, offering 3-, 6-, and 12-month plans with fixed monthly prices and potential savings up to $1,200/year for the injection and $600/year for the pill, via telehealth partners; the program aims to improve adherence and pre-empt competition from Eli Lilly’s upcoming oral GLP-1, and patients can opt out anytime (not yet on NovoCare DTC).

via CNBC|
#business#glp-1#novo-nordisk
Halting GLP-1 Meds Erases Cardiovascular Gains
heart-health21 days ago

Halting GLP-1 Meds Erases Cardiovascular Gains

A BMJ Medicine study of 333,687 veterans shows that stopping GLP-1 therapies (like Ozempic and Wegovy) reverses their cardiovascular benefits quickly: even a 6‑month lapse raises the risk of heart attack and stroke, and longer interruptions erode protection further. Continuous GLP-1 use was linked to fewer major cardiovascular events, while stopping can also lead to weight regain and withdrawal symptoms; tapering off with medical guidance and maintaining a healthy lifestyle is advised, underscoring that GLP-1 benefits are long‑term risk‑reduction rather than a quick fix.

via Healthline|
#cardiovascular#discontinuation#glp-1
FDA Clears Higher-Dose Wegovy to Boost Weight Loss
health22 days ago

FDA Clears Higher-Dose Wegovy to Boost Weight Loss

The FDA approved Wegovy HD, a 7.2 mg weekly dose of semaglutide, a higher-dose version expected to boost weight loss. In trials, the higher dose yielded about 19% body-weight loss (roughly 47 lb) vs 16% (about 39 lb) with the 2.4 mg dose over about 17 months; the drug will be available in April with price to be announced. European regulators had approved it earlier. Side effects were common (GI issues in 70%+; 23% reported skin sensations) and serious adverse events occurred in ~7% of the higher-dose group. The jump from 2.4 mg to 7.2 mg is substantial, and real-world safety will need monitoring. An oral Wegovy pill was approved by the FDA in December for context.

via ScienceAlert|
#fda#health#obesity-drug
FDA approves Wegovy HD, a higher-dose weight-loss option under a national priority program
health22 days ago

FDA approves Wegovy HD, a higher-dose weight-loss option under a national priority program

The FDA cleared Wegovy HD (7.2 mg) for weight loss and long-term maintenance in adults with obesity or overweight plus a weight-related condition, marking the fourth approval under the Commissioner’s National Priority Voucher program. The higher dose yielded greater average weight loss with a safety profile consistent with prior semaglutide doses, though GI side effects were common and there is a boxed warning for thyroid C-cell tumors; the approval was granted to Novo Nordisk, and a June public hearing on the voucher program is planned.

via fda.gov|
#fda#health#national-priority-voucher
FDA Approves Higher-Dose Wegovy to Narrow Gap with Zepbound
business23 days ago

FDA Approves Higher-Dose Wegovy to Narrow Gap with Zepbound

The FDA approved Novo Nordisk’s higher-dose Wegovy (7.2 mg) to improve weight loss outcomes, with phase 3 data showing about 20.7% average weight loss over 72 weeks; Novo plans an April launch to better compete with Eli Lilly’s Zepbound, which has demonstrated higher efficacy. A separate trial in obesity with Type 2 diabetes showed 14.1% weight loss, and the approval comes as the FDA pilots a faster review program for priority GLP-1 medications.

via CNBC|
#business#fda#novo-nordisk
Wegovy May Elevate Rare Eye Stroke Risk, Study Finds
science23 days ago

Wegovy May Elevate Rare Eye Stroke Risk, Study Finds

A large look at FDA adverse-event data suggests Wegovy (high-dose semaglutide) has a rare link to NAION, an “eye stroke” that can cause sudden vision loss, with men at higher risk than women. Wegovy shows a stronger association than Ozempic, possibly due to rapid weight loss and blood‑pressure fluctuations, but the overall risk remains very small and more research is needed.

via ScienceAlert|
#eye-stroke#naion#science
HIMS-Novo Wegovy Deal Triggers Bullish Analyst Revisions
market-news1 month ago

HIMS-Novo Wegovy Deal Triggers Bullish Analyst Revisions

Hims & Hers jumped about 49% after announcing a deal to offer Novo Nordisk’s Wegovy and Ozempic on its telehealth platform, a move that reduces legal risk as Novo dropped its lawsuit. Analysts at Citi, Deutsche Bank, Bank of America, and Needham issued more favorable views and higher price targets (up to about $30), signaling optimism that the partnership could unlock significant new revenue from official doses. TipRanks shows a Moderate Buy consensus with upside to current levels.

via TipRanks|
#glp-1#hims#market-news
FDA Warns Novo Nordisk for Underreporting Ozempic and Wegovy Adverse Events
health1 month ago

FDA Warns Novo Nordisk for Underreporting Ozempic and Wegovy Adverse Events

The FDA issued a warning letter to Novo Nordisk for serious postmarketing adverse drug event reporting violations related to the GLP-1 drugs Ozempic and Wegovy, citing three deaths (including a suicide) and a stroke report; the agency said Novo Nordisk failed to report deaths within the 15-day window and did not adequately investigate or report the suicide, though authorities have recently found no proven link between GLP-1s and suicide. Novo Nordisk has 15 days to report adverse reactions and two weeks to describe corrective actions; the company says it is addressing the concerns.

via WPXI|
#adverse-drug-events#fda#health
FDA flags Novo Nordisk for unreported side effects tied to Ozempic and Wegovy
health1 month ago

FDA flags Novo Nordisk for unreported side effects tied to Ozempic and Wegovy

The FDA sent Novo Nordisk a warning for serious lapses in reporting potential adverse events linked to semaglutide (the active ingredient in Ozempic and Wegovy), citing three deaths including a suicide and saying the company failed to investigate or report them within required timelines after an inspection of a New Jersey facility. Novo Nordisk says it will address the concerns, and the agency gave two weeks to outline corrective actions.

via NBC News|
#adverse-events-reporting#fda#health
Less Frequent GLP-1 Shots May Sustain Weight Loss, Small Study Finds
weight-loss1 month ago

Less Frequent GLP-1 Shots May Sustain Weight Loss, Small Study Finds

A small study of 30 adults suggests that reducing GLP-1 injections (tirzepatide or semaglutide) to intervals of 2–6 weeks can help maintain weight loss and improve health markers. Participants averaged about 36 weeks on reduced dosing with most keeping BMI stable; four regained some weight (largest gain 8 lb). Experts say tapering isn’t right for everyone and larger trials are needed, but this approach could lower long-term costs and treatment burden when paired with lifestyle changes.

via Healthline|
#glp-1#obesity#ozempic